Join PRA Health Sciences Vice President, Investigator Relations, Dr. Martin Lee, as he explores evidence based and site focused recruitment techniques for optimizing and accelerating clinical trial enrollment.
Our collaborative, cross-functional team develops tailored, cost-effective services to meet the unique needs of biosimilars clinical development.
PRA’s Unique Model Leads to Client Satisfaction
A randomized, multi-center, double-blind study to compare the efficacy and safety of Study Drug A and Study Drug B as monotherapy in newly diagnosed…
We’ve contributed to the successful approval of eight marketed cardiovascular and cardio-metabolic drugs.